Home › News & events › Innate Pharma moves forward anti-KIR monoclonal antibody IPH 2101 development with study extension in acute myeloid leukemia

Innate Pharma moves forward anti-KIR monoclonal antibody IPH 2101 development with study extension in acute myeloid leukemia

November 2, 2009
  • Other Phase I/II or IIa trials are planned with this drug candidate
  • In the context of the French new "anti-cancer plan" announcement, IPH 2101 was presented to government officials
Download Area
PR in english
CP en français